Triptorelin
Spectral Investigation of Human Tissue Using the Falcon-Ramon Molecular Imaging of Breast Cancer Samples Research Protocol Summary: This protocol is aimed at exploring the potential of molecular spectroscopy techniques applied to the study of breast cancer. General Eligibility: Participants with non-cancerous breast tumors and microscopic features of DCIS with various amounts of invasive cancer and calcifications as noted on pre-op core biopsy. * A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer SOFT trial ; Summary: This protocol is studying ovarian suppression with either tamoxifen or exemestane to see how well they work compared to tamoxifen alone in treating premenopausal women who have undergone surgery for hormone-responsive breast cancer. General Eligibility: Participants must have histologically confirmed breast cancer with the tumor confined to the breast and axillary nodes. Completely resected disease with no clinically detectable residual loco-regional axillary disease. Study Design: Participants may have had surgery alone or may have had surgery followed by chemotherapy. Participants will be randomized into one of 3 treatment groups. Group 1 will take Tamoxifen alone for 5 years. Group 2 will undergo Ovarian Function Suppression by taking triptorelin for 5 years OR surgical oophorectomy OR ovarian irradiation ; plus take Tamoxifen for 5 years. Group 3 will undergo Ovarian Function Suppression by taking triptorelin for 5 years OR surgical oophorectomy OR ovarian irradiation ; plus take Exemestane for 5 years. * Mammography Computer-Aided Detection CAD ; Study Retrospective Study ; Summary: The objective of this investigation is to obtain digital mammographic data for developing the formulas required for the development and testing of the Kodak Computer Aided Detection CAD ; System. General Eligibility: Screening and diagnostic cancer participants for whom all pathology information is at Allegheny General Hospital.
Triptorelin on line
Figure 1: Government budget for health as a percentage of the national budget. Venezuela, 19701999 [23] . 10 Figure 2: Political map of Venezuela and its 24 states . 15 Figure 3: Health committees, Mission Barrio Adentro, April 2003 May 2006 [67] . 41 Figure 4: Map of Amazonas State and Barrio Adentro health facilities . 52 Figure 5: Map of Libertador Municipio in Caracas and Barrio Adentro health facilities . 53 Figure 6: Total Barrio Adentro consultations in 2004-2005 . 87 Figure 7: Training of Mission Barrio Adentro health promoters, Venezuela, 2003-2006 [67] . 91 Figure 8: Update courses for trained health promoters, Venezuela, April 2003 to May 2006 [67] . 92 Figure 9: Training of young health promoters, Mission Barrio Adentro, May 2004 to May 2006 [67] . 93 Figure 10: Families visited by young health promoters, Mission Barrio Adentro, May 2004 to May 2006 [67] . 94 Figure 11: Membership in Expectant Mothers' Clubs, Mission Barrio Adentro, April 2003 to May 2006 [67] . 95 Figure 12: Membership in Baby Clubs, Mission Barrio Adentro, May 2004 to May 2006 [67] . 96 Figure 13: Membership in Teen Clubs, Mission Barrio Adentro, April 2003 to May 2006 [67] . 97 Figure 14: Membership in Seniors' Clubs, Mission Barrio Adentro, April 2003 to May 2006 [67] . 98 Figure 15: Number of radio stations carrying health education and promotion messages and average hours broadcast per week, by state, Venezuela [67] . 101.
Order generic Triptorelin
Cells were then treated with 1nm triptorelin for 9h or 1nm cetrorelix for 3h and stimulated for 3h with different concentrations of gnrh 10pm1m.
TRACLEER Bosentan ; . 18 tramadol. 22 TRANSDERM-SC DIS 1.5MG. 27 TRAVATAN SOL 0.004%. 25 trazodone hcl. 22 TRELSTAR DEP Triptorelin Pamoate ; . 13 TRELSTAR LA Triptorelin Pamoate ; . 13 tretinoin. 34 TREXALL . 13 triamcinolone acetonide mouth ; . 34 triamcinolone acetonide topical ; . 34 triamterene and hydrochlorothiazide . 23 TRICOR fenofibrate ; . 18 trifluoperazine hcl. 22 trifluridine . 25 TRIGLIDE fenofibrate ; . 18 trihexyphenidyl hcl. 14 TRILEPTAL Oxcarbazepine ; . 22 TRILYTE WITH FLAVOR . 27 trimethobenzamide hcl . 27 trimethoprim . 11 TRIOSTAT Liothyronine Sodium ; . 31 TRIPEDIA Diphtheria, Acellular Pertussis and Tetanus Toxoids ; . 32 TRISENOX Arsenic Trioxide ; . 13 TRIZIVIR Abacavir Sulfate-Lamivudine-Zidovudine ; . 11 TRUSOPT Dorzolamide HCl ; . 25 TRUVADA Emtricitabine-Tenofovir Disoproxil Fumarate ; . 11 trypsin w castor oil and peruvian balsam spr. 34 TWINRIX Hepatitis A Inactivated ; -Hepatitis B Recombinant ; Vaccines ; . 32 TYGACIL . 11 TYPHIM VI Typhoid VI Polysaccharide Vaccine ; . 32 TYPHOID VI SOLN . 32 UNIPHYL Theophylline ; . 35 UROCIT-K 10 Potassium Citrate Alkalinizer . 23 UROCIT-K 5 Potassium Citrate Alkalinizer . 23 URSO FORTE Ursodiol ; . 27 ursodiol . 27 VAGIFEM Estradiol Vaginal ; . 31 VALCYTE Valganciclovir HCl ; . 11 valproate sodium. 22 valproic acid . 22 VALTREX Valacyclovir HCl ; . 11 VANCOCIN HCL Vancomycin HCl ; . 11 vancomycin injection . 11 VANTIN SUSPENSION Cefpodoxime Proxetil ; . 11 * This prescription drug is not normally covered in a Medicare Prescription Drug Plan. The amount you pay when you fill a prescription for this drug does not count towards your total drug costs that is, the amount you pay does not help you qualify for catastrophic coverage.
| Triptorelin alcoholNOTES: 1. In the above Table 3A5.1., INVEST EXP indicates an item's monetary value and, in most cases, the source of funding. Investment INVEST ; indicates an expensive item. When the Logistics Readiness Squadron supply activity issues these items, there will be some form of accounting for the items. In most cases, investment items are paid for by the depot, MAJCOM, or Air Force. Expense EXP ; indicates an inexpensive item. When Logistics Readiness Squadron supply activity issues these items, no accounting is required except for XF items. Expense items are paid for with base-level funds organization ; . 2.For equipment items, the last position will contain the EMC. These codes are pushed by the item manager, except EMC 2 which is major command directed. EMC codes apply as explained above in Table 3A5.2.
Had of initial are The progressed age. and in two other off to the systemic third with were involvement when widespread 26 disease 1 and at was a few still of Four 5 years and trizivir.
LHRH challenge performed at 36 months of age Patient 1 ; and 18 months of age Patient 2 ; . Patient 1 treated with Nafrelin; Patient 2 treated with Decapeptyl Depot Triptorelin acetate.
|
Triptorelin 11.25mg vial Restricted to hospital initiation only. For Decapeptyl SR ; the treatment of precocious puberty and troleandomycin.
Triptorelin prescription
Triptorelin can be given for a period of weeks or even years.
MBTOC's review of the nominations showed that some research had commenced only in the past 2-3 years even though MB has been a controlled substance since 1992. In addition there were very few plans presented that indicated a path for the phase out of MB and the introduction of alternatives: a requirement for a critical use in Decision IX 6 para.1 b, iii ; , though many nominations documented the lengthy time period required for registration of new chemicals and the uncertainty that certain chemicals may not ultimately be registered despite evidence of efficacy. As a result, several CUNs contained information that showed the transition away from MB had not started sufficiently early to achieve orderly change to the alternative s ; to meet the 2005 phaseout schedule under the Protocol. Although a chemical may be progressively registered for various uses in the future, there will be delays in implementation due to the need for training, logistical and economic considerations. There is now insufficient lead time before 2005 to completely introduce a new technology across an industry or sector. In these cases MBTOC viewed 3 years as a reasonable estimate of the maximum period required for commercial scale up. Technically and economically feasible alternatives may well be available and implementable within the time frame of the nomination if they continue to be driven by the incentive of phaseout of MB. MBTOC supported CUNs for uses where feasible alternatives are available but still required time to implement. MBTOC notes that prolonged authorisations of MB would discourage further development and introduction of these alternatives when alternatives have not yet achieved high penetration into the market or sufficient commercial availability. Timely implementation of technically and economically feasible alternatives in non-Article 5 1 ; countries could result in technology being available to accelerate the phaseout in Article 5 1 ; countries. On the other hand lack of early research for specific uses has delayed registration and implementation of alternatives, and slowed MB phase-out. Continued use of MB in developed countries would result in pressures to retain MB in Article 5 1 ; countries. Some CUNs from non-Article 5 1 ; countries are for uses, which some enterprises in Article 5 1 ; countries have already phased out. Unless this is fully justified, it could jeopardise MB phase-out efforts in both Article 5 1 ; and non-Article 5 1 ; parties. Furthermore it may diminish the opportunities for non-Article 5 1 ; countries to learn from the technical developments made in Article 5 1 ; countries and trovafloxacin.
FIG. 6. Merbarone does not affect topoisomerase II-mediated ATP hydrolysis. ATPase reactions contained 50 nM human topoisomerase II , 40 nM pBR322 plasmid DNA, and 1 mM [ -32P]ATP. A time course of ATP hydrolysis was performed at 0 M 200 M E ; merbarone. Three independent assays were carried out for each drug concentration. Error bars depict standard deviations.
Figure 2. The malaria parasite life cycle and the site of action of antimalarial drugs figure and truvada.
Played no part in the growth-promoting effect of the antibiotics. The carcasses of rats that grew at an accelerated rate while eating antibioticenriched diets in experiments 1 and 2 con tained normal amounts of nitrogen, water, and lipid. This suggests that protoplasm, extracellular fluid and adipose tissue were.
Prolactin PRL; 8.4; normal range, 23 ng ml ; levels. Ovarian ultrasonography revealed a 2.8-cm left ovarian solid tumor and slight enlargement of the right ovary. Computer tomography CT ; and magnetic resonance imaging MRI ; of the pituitary did not reveal any pathology. The patient underwent resection of the left ovarian tumor and a wide wedge resection of the right; histology revealed a typical thecoma with nodular hyperthecosis of the resected right ovarian wedge. Postoperatively, androgen serum levels markedly decreased [total testosterone, 0.60 ng ml 2.1 nmol liter; normal range, 0.2 0.9 ng ml FT, 2.30 pg ml 7.98 pmol liter 4A, 3.29 ng ml 11.5 nmol liter ; ], but serum LH levels remained markedly elevated at 220 IU liter. Because pituitary imaging was negative, a presumptive diagnosis of severe PCOS was made, and the patient was started on treatment with a long-acting GnRH analog triptorelin depot, 3.75 mg month ; for 3 months. This treatment was not associated with any substantial reduction of the elevated LH serum levels LH, 98 220 IU liter in addition, serum androgens raised again to the postoperative levels [FT, 17.16 21.57 pg ml 59.574.8 pmol liter ; ]. For 4 months before her current admission, she received no medication. On admission, she was found to be normotensive 125 75 mm Hg ; , but overweight body mass index, 27 kg m2 ; . Clinical examination revealed marked acne on the face and neck, hirsutism, and virilism. Terminal hair was present beneath the chin, on the upper lip, the sideburn area, about the areola, and over the presternal region. The pubic hair extended along the midline to the umbilicus and involved the medial aspects of the thighs. Muscle bulk was increased, and she had mild grade II ; clitoromegaly, but no acanthosis nigricans; the rest of the clinical and gynecological examination showed no abnormalities. Routine hematology and biochemistry were normal. Serum androgen [ 4A, 19.98 ng ml 69.8 nmol liter FT, 21.57 pg ml 74.8 pmol liter 17hydroyprogesterone, 7.92 ng ml 24 nmol liter; normal range, 0.11.0 ng ml ; ] and LH 203 IU liter ; levels were elevated, whereas estradiol E2 ; [92.34 pg ml 339 pmol liter ; ], PRL 10.6 ng ml ; , DHEA-S [254 g dl 6.9 mol liter ; ], and FSH 3 IU liter ; were within the normal range; SHBG [22.9 nmol liter; normal range, 20 120 nmol liter ; levels were significantly reduced. She underwent an oral glucose tolerance test 75 g glucose, orally ; , which revealed normal glucose tolerance with mild hyperinsulinemia insulin: 0 min, 11.3; 30 min, 65.4; 60 min, 101.3; 90 min, 107.1; 120 min, 113.6 U ml ; . Thereafter, the patient received octreotide, a long-acting somatostatin analog 200 g 6 h for 3 d ; , which resulted in significant reduction of serum LH levels before, 220 IU liter; after, 104 IU liter ; . A repeated MRI scan of the pituitary showed no evidence of a pituitary lesion, and a transvaginal ultrasonographic pelvic examination revealed a normal uterus with an 8-mm endometrium and a 2.2-cm solid tumor of the right ovary. After substantial reduction of serum LH levels following the administration of octreotide, additional imaging with helical CT scan of the chest, CT and MRI of the abdomen, as well as a whole body [111In]octreotide scan octreoscan ; were suggested. However, because of the severity of the symptoms signs of hyperandrogenism and their apparent relation to the tumor of the ovary, the patient decided to have a right ovariectomy in a private maternity hospital. Histology also disclosed a typical thecoma. Two months later, the patient was readmitted to this hospital for additional investigation. Although postoperative serum androgen and E2 levels fell within or below the normal range [total testosterone, 0.39 ng ml 1.38 nmol liter FT, 1.5 pg ml 5.2 pmol liter 4 , 0.9 ng ml 3.14 nmol liter E2, 8.17 pg ml 30 pmol liter ; ], serum LH remained grossly elevated LH, 238.8 IU liter; FSH, 48.4 IU liter ; . Both the CT and and tums.
FIG. 7. Activation of Cl currents by BzATP. SMG duct af ; and acinar gl ; cells were stimulated with 25 M BzATP. The pipette solution contained either 0.5 a, c, g, and i ; or 5 EGTA e and j ; . Where indicated, the cells were perfused with a Ca2 -free bath solution a and g ; or a bath solution containing 100 M glibenclamide Gli ; c, e, i, and j ; . Ca2 -dependent b and h, traces 2 and 3 ; and Ca2 -independent, glibenclamide sensitive currents traces 3-1 in b and h, and traces 2-3 in d, f, k, and l ; derived from the current voltage relationships are summarized in Table I.
Cotrimoxazole 400 80 mg tab 2 bd x days Chloroquine 150 mg tab 4 stat, then 2 tab bd x 2 Either dispense all the 20 tablets of cotrimoxazole or the 10 tablets of chloroquine as prescribed and insist that the patient completes the dose dispensed. In case a patient is unable to pay for all the prescribed drugs, go to the prescriber and ask which of the two drugs should be dispensed first and tysabri.
Hoped to lead to significant improvement in the results ofcancer therapy. After 16 years of clinical application of hyperbaric oxygen as an adjunct to radiation therapy, it has become apparent that the clinical results have not lived up to the high expectations which seemed justified from the expenimental results. The reasons for this discrepancy are still obscure. However, an examination of time-dose schedules is in order: Time-dose schedules used by various investigatons fall essentially into 3 categories: I ; 4 to fractions in 3 to weeks; 2 ; 10 to 12 fractions in 3 to weeks; and , ; 20 to 40 fractions in 5 to weeks. Churchill-Davidson and van den Brenk, having to use anesthesia in their earlier work, were forced to use fewer and larger fractions. The high incidence of necrosis caused van den Brenk1' to shift from the 2 on 3 times 8oo to i , ooo rads to 6 times 550 to 6oo rads with significant improvement in results and decrease in the rate of necrosis and triptorelin.
Chua, S.E. dhe McKenna, P.J. "Schizophrenia A Brain Disease?" British Journal of Psychiatry 166: 563-82 1995 ; . Ciompi, L. dhe Moller, C. Lebenswegund Alter der Schizophrenie: Eine Katamnestische Lonzenstudies Bis ins Senium. Berlin: Verlig, 1976. Davidson, L. dhe Strauss, J. "Sense of Self in Recovery from Severe Mental Illness." British Journal of Medical Psychology 65: 131 145 ; . Davidson, L. dhe Strauss, J. "Beyond the Biopsychosocial Model: Integrating Disorder, Health, and Recovery." Psychiatry 58: 55-60 1995 ; . Deegan, P. "Recovery: the Lived Experience of Rehabilitation." Journal of Psychosocial Rehabilitation 11: 167-170 1988 ; . DeMasi, M.; Markowitz, F.; Videka-Sherman, L.; Knight, E.; dhe Carpinella, S.E. "Specifying the Dimensions of Recovery." Paper presented on 6th Annual National Conference on State Mental Health Agency Services Research and Program Evaluation, Arlington, VA 1996 ; . DeSisto, M.; Harding, C.; McCormick, R.; Ashikaga, T.; dhe Brooks, G. "The Maine and Vermont Three-Decade Studies of Serious Mental Illness, Parts 1 and 2." British Journal of Psychiatry 167: 331-342 1995 ; . Fisher, D. Hope, "Humanity and Voice in Recovery from Psychiatric Disability." The Journal, 5: 13-15 1994 ; . Fisher, D. dhe Deegan, P. "Final Report on Recovery Project." Rockville, MD: Center for Mental Health Services, 1998. Greenberg, J. I Never Promissed You a Rose Garden. New York: Dutton, NY, 1989 and ubiquinone!
An aunt of mine died recently in her eighties from a perforated bowel. She also had numerous other illnesses that, singly or in combination, would eventually have killed her. It was a matter of which illness got her first. She longed to die. "I pray to God to take me now, " she would say. But she lingered for months and suffered physically and mentally. She was so debilitated by her illnesses that life gave her no pleasure. While she recognized my work in the field of euthanasia, and spoke approvingly of it, her religious beliefs would not permit her to accelerate the end in any way. I respected that. A willingness to die is insufficient alone to bring about death. It would be nice if that were all that were necessary. I have heard direct accounts of people who were terribly.
Aboulghar, M., Mansour, R., Serour, G. et al. 1998 ; Recombinant follicle stimulating hormone in the treatment of patients with history of severe ovarian hyperstimulation syndrome. Fertil. Steril., 69 Suppl. 1 ; , 72S75S Ben-Chetrit, A., Gotleib, L., Wong, P.Y. and Casper, R. 1998 ; Ovarian response to recombinant human follicle-stimulating hormone in luteinizing hormonedepleted women: examination of the two cell two gonadotrophin theory. Fertil. Steril., 69 Suppl. 2 ; , 59S65S. Chappel, S.C. and Howles, C. 1991 ; Revaluation of the roles of luteinizing hormone and follicle stimulating hormone in the ovulatory process. Hum. Reprod., 6, 12061212. Couzinet, B., Lestrat, N., Brailly, S. et al. 1988 ; Stimulation of ovarian follicular maturation with pure follicle stimulating hormone in women with gonadotrophin deficiency. J. Clin. Endocrinol. Metab., 66, 552556. Erickson, G.F. and Hsueh, A.J.W. 1978 ; Stimulation of aromatase activity by follicle stimulating hormone in rat granulosa cells in vivo and in vitro. Endocrinology, 102, 12751283. Feldberg, D., Farhi, J., Ashkenazi, J. et al. 1994 ; Minidose gonadotrophinreleasing hormone agonist is the treatment of choice in poor responders with high follicle-stimulating hormone levels. Fertil. Steril., 62, 343346. Fevold, H. 1941 ; Synergism of follicle stimulating and luteinizing hormones in producing estrogen secretion. Endocrinology, 28, 3336. Filicori, M. 1996 ; Clinical review 81: Gonadotrophin-releasing hormone analogues in ovulation induction: current status and perspectives. J. Clin. Endocrinol. Metab., 81, 24132416. Filicori, M. 1999 ; The role of luteinizing hormone in folliculogenesis and ovulation induction. Fertil. Steril., 71, 405414. Fleming, R., Lloyd, F., Herbert, M. et al. 1998 ; Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle stimulating hormone. Hum. Reprod., 13, 17881792. Fleming, R., Rehka, P., Deshpande, N. et al. 2000 ; Suppression of LH during ovarian stimulation: effects differ in cycles stimulated with purified urinary FSH and recombinant FSH. Hum. Reprod., 15, 14401445. Hedon, B., Out, H., Hughues, J. et al. 1995 ; Efficacy and safety of recombinant follicle stimulating hormone Puregon ; in infertile women pituitarysuppressed with triptorelin undergoing in vitro fertilisation: a prospective, randomised, assessor-blind, multicentre trial. Hum. Reprod., 10, 31023106. Hughes, E.G., Fedorkow, D.M., Daya, S. et al. 1992 ; The routine use of gonadotrophin-releasing hormone agonists prior to in-vitro fertilisation and gamete intrafallopian transfer: a meta-analysis of randomised controlled trials. Fertil. Steril., 58, 888896. Huhtaniemi, I., Jiang, M., Nilsson, C. and Pettersson, K. 1999 ; Mutations and polymorphisms in gonadotropin genes. Mol. Cell. Endocrinol., 25, 8994. Jiang, M., Pakarinen, P., Zhang, F.P. et al. 1999 ; . A common polymorphic allele of the human luteinizing hormone beta-subunit gene: additional mutations and differential function of the promoter sequence. Hum. Mol. Genet., 8, 20372046. Laml, T., Obruca, A., Fischl, F. and Huber, J. 1999 ; Recombinant luteinizing hormone in ovarian hyperstimulation after stimulation failure in normogonadotrophic women. Gynecol. Endocrinol., 13, 98103. ` Levy, D., Navarro, J., Schattman, G. et al. 2000 ; The role of LH in ovarian stimulation: exogenous LH, let's design the future. Hum. Reprod., 15, 22582265. Liu, Z., Andoh, K., Mizunuma, H. et al. 2000 ; Effects of recombinant human FSH rhFSH ; , urinary purified FSH uFSH ; , and hMG on small preantral follicles and tertiary follicles from normal adult and androgen-sterilized female mice. Fertil. Steril., 73, 372380. Loumaye, E., Engrand, P., Howles, C.M. and O'Dea, L. 1997 ; Assessment of the role of serum luteinising hormone and estradiol response to folliclestimulating hormone on in-vitro fertilisation treatment outcome. Fertil. Steril., 67, 889899. Ludwig, M., Finas, D.F., al-Hasani, S. et al. 1999 ; Oocyte quality and treatment outcome in intracytoplasmic sperm injection cycles of polycystic ovarian syndrome patients. Hum. Reprod., 14, 354358 and ursinus.
3 3.1 A Category 1 drug product is a new DIN of an existing dosage form of an existing medicine, or a new DIN of another dosage form of the medicine that is comparable to the existing dosage form as per Schedule 7. A Category 2 drug product is one that provides a breakthrough or substantial improvement. It is a new DIN of a non-comparable dosage form of an existing medicine or the first DIN of a new chemical entity. A Category 3 drug product is a new DIN of a non-comparable dosage form of an existing medicine or the first DIN of a new chemical entity. These DINs provide moderate, little or no therapeutic advantage over comparable medicines. This group includes those new drug products that are not included in Category 2 above and trizivir.
Product Bemiparin Zibor ; Buprenorphine patch Transtec ; Buprenorphine transdermal patch BuTrans ; Buprenorphine naloxone Suboxone ; Clarithromycin granules ClaroSip ; Cinacalcet Mimpara ; Diclofenac gel patch Voltarol ; Drospirenone ethinylostradiol Yasmin ; Epinastine eye drops Relestal ; Esomeprazole Nexium ; Estradiol drospirenone Angeliq ; Fondaparinux Arixtra ; Fulvestrant Faslodex ; Glyceryl trinitrate anal ointment Rectogesic ; Grazax - extract of grass pollen Ivabradine Ketotifen eye drops Zaditen ; Lidocaine 5% medicated plaster Versatis ; Macrogol 4000 Idrolax ; Memantine Ebixa ; Metformin prolonged release Glucophage SR ; Methotrexate inj Metoject ; Modafinil Provigil ; Moxifloxacin Avelox ; Nebivolol Nebilet ; Nicotinic acid MR Niaspan ; Omalizumab Xolair ; 90% omega-3-acid ethyl esters Omacor ; Oxycodone OxyNorm ; injection Pregabalin Lyrica ; Rasagiline Azilect ; Rimonabant Acomplia ; Rivastigmine Exelon ; Rotigotine transdermal patch Neupro ; Sertraline Lustral ; Sodium oxybate Xyrem ; Testosterone injection Nebido ; Tramadol paracetamol Tramacet ; Triptorelin Gonapeptyl depot ; Zoledronic acid Zometa ; Product Abacavir Ziagen ; Abacavir lamivudine Kivexa ; Adefovir Hepsera ; Anagrelide Xagrid ; Caspofungin Cancidas ; Cinacalcet Mimpara ; Deferasirox Exjade ; Emtricitabine Emtriva ; Emtricitabine tenofovir Truvada ; Enfuvirtide Fuzeon ; Entecavir Ertapenem Invanz ; Fosamprenavir Telzir ; Ibandronic acid IV Bonviva ; Lopinavir ritonavir tablets Kaletra ; Moxifloxacin Avelox ; Paracetamol IV infusion Posaconazole Risperidone orodispersible tablets Risperdal ; Risperidone depot injection Risperdal Consta ; Tenofovir Viread ; Teriparatide Forsteo ; Tigecycline Tygacil ; Tipranavir Aptivus ; Trastuzumab Herceptin ; Triptorelin Decapeptyl SR ; Valganciclovir Valcyte ; Voriconazole VFEND ; Zoledronic acid Aclasta ; Zoledronic acid Zometa ; Indication DVT prophylaxis; DVT treatment Moderate to severe pain Severe opioid responsive pain conditions Opioid drug dependence Acute and chronic infections Hypercalcaemia in parathyroid carcinoma Epicondylitis, ankle sprain Oral contraceptive Seasonal allergic conjunctivitis Healing of NSAID associated gastric ulcers, prevention of NSAID gastric duodenal ulcers Prevention of postmenopausal osteoporosis; prevention of menopausal symptoms VTE prevention in high risk medical patients, Acute DVT PE treatment Advanced breast cancer Chronic anal fissure Grass pollen induced rhinitis and conjunctivitis Angina Allergic conjunctivitis Post-herpetic neuralgia Constipation Alzheimer's Disease Diabetes Severe active rheumatoid arthritis in adults Obstructive sleep apnoea hypopnoea; shift work sleep disorder Infective exacerbations of COPD Chronic heart failure Dyslipidaemia Severe persistent allergic asthma Hypertriglyceridaemia Post-operative pain Neuropathic pain, generalised anxiety disorder in adults Parkinson's Disease Adjunct to diet and exercise for the treatment of obese patients Mild to moderately severe dementia in patients with Parkinson's disease Parkinson's Disease Post traumatic stress disorder Cataplexy with narcolepsy Hypogonadism Moderate to severe pain Prostate cancer, Endometriosis Metastatic bone disease associated with prostate cancer Indication HIV HIV Hepatitis B Thrombocythaemia Invasive candidiasis; empirical antifungal in febrile, neutropenic patients. Secondary hyperparathyroidism in end-stage renal disease Chronic iron overload HIV HIV HIV Hepatitis B Intra-abdominal infections HIV Postmenopausal osteoporosis HIV-1 Community acquired pneumonia Short term pain, fever Specific invasive fungal infections Schizophrenia Schizophrenia HIV Severe osteoporosis in post-menopausal women Complicated skin and soft-tissue infections, complicated intra-abdominal infection cIAI ; HIV HER2 positive early breast cancer Precocious puberty CMV retinitis in AIDS patients; prevention of CMV retinitis post organ transplant Invasive aspergillosis; serious fungal infections; candidaemia in non-neutropenic patients Paget's disease Metastatic bone disease associated with breast cancer and valcyte.
|
